AbbVie Investor Says Brass Exposed Co. To Off-Label Claims

An AbbVie Inc. shareholder launched a derivative suit Thursday in Delaware Chancery Court accusing the biopharmaceutical company’s brass of saddling it with the risk of liability connected to whistleblower accusations of physician kickbacks and off-label drug marketing directed at former parent Abbott Laboratories before a spinoff.